Lipoic acid ( DrugBank: Lipoic acid )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2
5	進行性核上性麻痺	1
13	多発性硬化症／視神経脊髄炎	7
14	慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー	1
20	副腎白質ジストロフィー	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04518540 (ClinicalTrials.gov)	September 1, 2020	5/8/2020	Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis	Randomized, Parallel Safety and Efficacy Study of Lipoic Acid in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: lipoic acid group;Drug: control group	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	20 Years	75 Years	All	150	N/A	China
2	EUCTR2005-005152-40-IT (EUCTR)	19/04/2006	07/04/2006	MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALS	MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALS	ALS MedDRA version: 6.1;Level: PT;Classification code 10002026	Product Name: ALPHA-LIPOIC ACID INN or Proposed INN: Tioctic acid	AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	84		Italy

5. 進行性核上性麻痺

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01537549 (ClinicalTrials.gov)	September 14, 2010	9/1/2012	Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy	An Open-label Trial of Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy (PSP): Effect Upon Oxidative Damage and Mitochondrial Biomarkers	Progressive Supranuclear Palsy	Drug: alpha-lipoic acid and L-acetyl carnitine	Weill Medical College of Cornell University	NULL	Completed	40 Years	75 Years	All	11	Phase 1/Phase 2	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03161028 (ClinicalTrials.gov)	July 1, 2018	18/5/2017	Lipoic Acid for Progressive Multiple Sclerosis (MS)	Lipoic Acid for the Treatment of Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Lipoic acid;Drug: Placebo	VA Office of Research and Development	NULL	Active, not recruiting	18 Years	70 Years	All	115	Phase 2	United States;Canada
2	NCT03493841 (ClinicalTrials.gov)	June 8, 2018	21/3/2018	Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis	Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial	Multiple Sclerosis;Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Alpha Lipoic Acid	Rebecca Spain	NULL	Completed	18 Years	N/A	All	20	Phase 1	United States
3	NCT02133664 (ClinicalTrials.gov)	June 2014	6/5/2014	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis	Multiple Sclerosis;Cognition	Drug: lipoic acid and omega-3 fatty acids;Drug: Placebo	Oregon Health and Science University	National Multiple Sclerosis Society	Completed	18 Years	65 Years	All	54	Phase 1/Phase 2	United States
4	NCT01188811 (ClinicalTrials.gov)	October 2010	25/8/2010	Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)	Lipoic Acid for Neuroprotection in Secondary Progressive MS	Multiple Sclerosis, Chronic Progressive	Drug: lipoic acid;Drug: Placebo	VA Office of Research and Development	Oregon Health and Science University	Completed	40 Years	70 Years	All	54	Phase 2/Phase 3	United States
5	NCT00997438 (ClinicalTrials.gov)	August 2010	16/10/2009	Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis	Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis	Multiple Sclerosis	Dietary Supplement: Lipoic Acid	Portland VA Medical Center	Oregon Health and Science University	Completed	18 Years	N/A	All	69	Phase 1	United States
6	NCT00676156 (ClinicalTrials.gov)	December 2005	7/5/2008	A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis	A Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple Sclerosis	Multiple Sclerosis	Drug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acid	Oregon Health and Science University	National Center for Complementary and Integrative Health (NCCIH)	Completed	18 Years	80 Years	Both	40	Phase 1	United States
7	NCT00010842 (ClinicalTrials.gov)	September 1999	2/2/2001	Natural Antioxidants in the Treatment of Multiple Sclerosis	Natural Antioxidants in the Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acids	National Center for Complementary and Integrative Health (NCCIH)	NULL	Completed	N/A	N/A	Both		Phase 1/Phase 2	United States

先頭へ

14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー

臨床試験数 : 175 / 薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00962429 (ClinicalTrials.gov)	February 2009	19/8/2009	Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy	Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study	CIDP;Chronic Inflammatory Demyelinating Polyneuropathy	Drug: lipoic acid	Oregon Health and Science University	Collins Medical Trust	Completed	18 Years	80 Years	All	7	Phase 2	United States

20. 副腎白質ジストロフィー

臨床試験数 : 61 / 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01495260 (ClinicalTrials.gov)	September 2011	28/11/2011	A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants	A Clinical Trial for Adrenomyeloneuropathy (AMN): Validation of Biomarkers of Oxidative Stress, and Efficacy, Tolerance and Safety of a Mixture of the Antioxidants N-acetylcysteine, Lipoic Acid and Vitamin E	Adrenomyeloneuropathy	Drug: N-acetylcysteine;Drug: lipoic acid;Drug: vitamin E	Onofre, Aurora Pujol, M.D.	Ministerio de Sanidad, Servicios Sociales e Igualdad;Fundacion Hesperia	Completed	18 Years	64 Years	All	13	Phase 2	Spain

先頭へ